Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C5RE | ISIN: NL0015000HT4 | Ticker-Symbol: 63E
Frankfurt
25.04.24
09:59 Uhr
4,700 Euro
-0,010
-0,21 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ONWARD MEDICAL NV Chart 1 Jahr
5-Tage-Chart
ONWARD MEDICAL NV 5-Tage-Chart
RealtimeGeldBriefZeit
4,8204,83011:12

Aktuelle News zur ONWARD MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07:34ONWARD Medical NV: ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date315Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital Announced positive top-line results from Up-LIFT pivotal study Forged partnership to provide...
► Artikel lesen
11.04.ONWARD Medical NV: ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast304EINDHOVEN, the Netherlands, April 11, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement...
► Artikel lesen
09.04.ONWARD Medical NV: Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00391EINDHOVEN, the Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence...
► Artikel lesen
02.04.ONWARD Medical NV: ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System546FDA clearance would allow the Company to market its breakthrough therapy to improve or restore hand and arm function after spinal cord injury in the USTHIS PRESS RELEASE CONTAINS INSIDE INFORMATION...
► Artikel lesen
25.03.ONWARD Medical NV: ONWARD® Medical Publishes Closing of Accelerated Bookbuild Offering and Public Offering in France870NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER...
► Artikel lesen
21.03.ONWARD Medical NV: ONWARD® Medical Publishes Prospectus for Listing of New Shares337NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER...
► Artikel lesen
21.03.ONWARD Medical NV: ONWARD® Medical Successfully Raises €20 Million in a Capital Increase by Way of an Accelerated Bookbuild Offering and by Way of a Public Offering in France357NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER...
► Artikel lesen
20.03.ONWARD Medical NV: ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option238EINDHOVEN, the Netherlands, March 20, 2024 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION...
► Artikel lesen
18.03.ONWARD Medical NV: ONWARD® Medical Successfully Completes Benchmark Testing on Path to Commercialize ARC-EX® System473Third-party tests from leading US lab confirm printed circuit board assembly (PCBA) conforms to prevailing international electrical standards, a requirement for commercial launch THIS PRESS RELEASE...
► Artikel lesen
15.03.ONWARD Medical NV: ONWARD® Medical Reaffirms Guidance, Shares 2024 Strategic Priorities, and Releases Unaudited Q4 Financial Highlights312THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Company expects to commercialize its ARC-EX® System and...
► Artikel lesen
15.03.ONWARD Medical NV: ONWARD verstärkt Führungsteam auf Schlüsselpositionen in den Bereichen Clinical & Regulatory sowie Marketing349Erika Ross wird zur VP Global Clinical & Regulatory ernannt, Sarah Moore kommt als VP Global Marketing zum UnternehmenEINDHOVEN, Niederlande, LAUSANNE, Schweiz und BOSTON, MA, March 15, 2024 (GLOBE...
► Artikel lesen
11.03.ONWARD Medical NV: ONWARD® Medical Accepted to New US FDA TAP Program for Development of its ARC-BCI System441The Company is one of the first brain-computer interface entrants accepted into this program, intended to optimize the commercialization pathway for breakthrough medical technology EINDHOVEN, the Netherlands...
► Artikel lesen
29.02.ONWARD Medical NV: ONWARD® Medical Awarded 10th Breakthrough Device Designation for Brain-Computer Interface (BCI) from US FDA870Award gives priority US regulatory review to Company's ARC-BCI System EINDHOVEN, the Netherlands, Feb. 29, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company...
► Artikel lesen
09.02.ONWARD Medical NV: KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 10.00 Per Share423EINDHOVEN, the Netherlands, Feb. 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence...
► Artikel lesen
07.02.ONWARD Medical NV: ONWARD® MEDICAL ANNOUNCES PRESENTATION AT BIOCAPITAL EUROPE679CEO Dave Marver will present on the Company's use of brain-computer interface technology and progress toward planned commercialization of ARC-EX® later this year EINDHOVEN, the Netherlands, Feb. 07...
► Artikel lesen
25.01.ONWARD Medical NV: ONWARD® ARC Therapy Highlighted at 2024 Annual Meeting of the North American Neuromodulation Society (NANS)1.114Clinical experience with investigational ARC-EX® Therapy showcased on the main stage and in clinical abstracts during the 2024 NANS Annual Meeting EINDHOVEN, the Netherlands, Jan. 25, 2024 (GLOBE NEWSWIRE)...
► Artikel lesen
22.01.ONWARD Medical NV: ONWARD® to Participate in Basel Healthtech Conference 2024381CEO Dave Marver will discuss the Company's leadership in health technology, including spinal cord stimulation with brain-computer interfacesEINDHOVEN, the Netherlands, Jan. 22, 2024 (GLOBE NEWSWIRE)...
► Artikel lesen
19.01.ONWARD Medical NV: ONWARD® to Participate in Degroof Petercam Healthcare Conference430CEO Dave Marver will provide update on the Company's progress toward launch of its first therapy later this yearEINDHOVEN, the Netherlands, Jan. 19, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext:...
► Artikel lesen
18.01.ONWARD Medical NV: ONWARD® Announces Start of HemON NL Clinical Study441HemON NL is evaluating the use of ARC-IM® Therapy to address hemodynamic instability after spinal cord injury EINDHOVEN, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext:...
► Artikel lesen
16.11.23ONWARD Medical NV: ONWARD verstärkt Führungsteam auf Schlüsselpositionen in den Bereichen Clinical & Regulatory sowie Marketing425Erika Ross wird zur VP Global Clinical & Regulatory ernannt, Sarah Moore kommt als VP Global Marketing zum UnternehmenEINDHOVEN, Niederlande, LAUSANNE, Schweiz und BOSTON, MA, Nov. 16, 2023 (GLOBE NEWSWIRE)...
► Artikel lesen
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1